Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment

Jin, Xin; Zhou, Jianping; Zhang, Zhenhai; Lv, Huixia

doi:10.1016/j.ijpharm.2019.118751

Cited by 27 publications

(11 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Common chemotherapy drugs are gemcitabine, docetaxel, pemetrexed, paclitaxel, and some platinums, including cisplatin, carboplatin, and some nedaplatin. While, due to the drug resistance of some tumors, chemotherapy drugs cannot successfully achieve the expected effect of tumor treatment, so some combination therapy through chemotherapeutic sensitizing agent [such as, lonidamine (86)(87)(88)(89)(90), poloxamers, silibinin (91)], immune checkpoint inhibitors [such as PD-1 inhibitors, PD-L1 inhibitors (92)], enzyme related inhibitors [such as ribonucleotide reductase inhibitors, crizotinib (93)], as well as other tumor-related inhibitors have become a research hotspot. High atomic element (Z) nanomaterials, such as bismuth (Z=83), gold (Z=79), tungsten (Z=74), tantalum (Z=73), hafnium (Z=72), tellurium (Z=52), silver (Z=47), are capable of increasing the production of secondary and Auger electrons, which in turn increases the generated ROS and enhances the deposition of radiation.…”

Section: Common Sensitizing Agentmentioning

confidence: 99%

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Carbon ion radiation therapy (CIRT) is the most advanced radiation therapy (RT) available and offers new opportunities to improve cancer treatment and research. CIRT has a unique physical and biological advantage that allow them to kill tumor cells more accurately and intensively. So far, CIRT has been used in almost all types of malignant tumors, and showed good feasibility, safety and acceptable toxicity, indicating that CIRT has a wide range of development and application prospects. In addition, in order to improve the biological effect of CIRT, scientists are also trying to investigate related sensitizing agents to enhance the killing ability of tumor cells, which has attracted extensive attention. In this review, we tried to systematically review the rationale, advantages and problems, the clinical applications and the sensitizing agents of the CIRT. At the same time, the prospects of the CIRT in were prospected. We hope that this review will help researchers interested in CIRT, sensitizing agents, and radiotherapy to understand their magic more systematically and faster, and provide data reference and support for bioanalysis, clinical medicine, radiotherapy, heavy ion therapy, and nanoparticle diagnostics.

show abstract

Section: Common Sensitizing Agentmentioning

confidence: 99%

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Wang

Chen

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…It was not surprising that the tumor growth delay for DB-1 melanoma (25.4 days) was more obvious than that of WM983B (13.7 days) after the combination treatment of LND plus DOX, because WM983B melanoma cells are less energetic than DB-1 cells, LND-mediated energy depletion should be less in WM983B tumors, thus being less effective in increasing the activity of DOX. Recently, Jin et al constructed an all-in-one multifunctional pH-sensitive tumor-targeted delivery system, where LND is used as a chemosensitizer and DOX as a chemotherapeutic agent were integrated into a micelle [81]. The unique pH-sensitive DOX/LND micelle displayed effective targeting to tumor sites, resulted in burst release of DOX under acid tumor microenvironment (~pH 6.5).…”

Section: Lnd In Combination With Anthracyclinesmentioning

confidence: 99%

“…More importantly, the novel micelle system reduced the DOX-induced cardiac fibrosis and hematological toxicity. Further studies showed that the underlying mechanisms of better therapeutic effects include (1) LND-induced ATP deprivation decreases the supply of energy for MDR efflux pumps, more drugs (DOX) were retained in tumor cells, (2) mitochondria-dependent apoptosis, (3) antiangiogenic effect, and (4) effective killing of cancer stem cells [81].…”

Section: Lnd In Combination With Anthracyclinesmentioning

confidence: 99%

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment

Huang

Sun

et al. 2020

Cancers

View full text Add to dashboard Cite

Lonidamine (LND) has the ability to resist spermatogenesis and was first used as an anti-spermatogenic agent. Later, it was found that LND has a degree of anticancer activity. Currently, LND is known to target energy metabolism, mainly involving the inhibition of monocarboxylate transporter (MCT), mitochondrial pyruvate carrier (MPC), respiratory chain complex I/II, mitochondrial permeability transition (PT) pore, and hexokinase II (HK-II). However, phase II clinical studies showed that LND alone had a weak therapeutic effect, and the effect was short and reversible. Interestingly, LND does not have the common side effects of traditional chemotherapeutic drugs, such as alopecia and myelosuppression. In addition, LND has selective activity toward various tumors, and its toxic and side effects do not overlap when combined with other chemotherapeutic drugs. Therefore, LND is commonly used as a chemosensitizer to enhance the antitumor effects of chemotherapeutic drugs based on its disruption of energy metabolism relating to chemo- or radioresistance. In this review, we summarized the combination treatments of LND with several typical chemotherapeutic drugs and several common physical therapies, such as radiotherapy (RT), hyperthermia (HT), and photodynamic therapy (PDT), and discussed the underlying mechanisms of action. Meanwhile, the development of novel formulations of LND in recent years and the research progress of LND derivative adjudin (ADD) as an anticancer drug were also discussed.

show abstract

“…6 Lonidamine (LND) was found to have anticancer activity by sensitizing tumors to various therapies like chemo-, radio-, and photodynamic-therapy and hyperthermia. 7 As a chemosensitizer, lonidamine combined with doxorubicin (DOX, an effective broad-spectrum anticancer drug) to synergistically treat liver cancer, 8 ovarian cancer, 9 or breast cancer 10 was reported to make progress. However, the combination of DOX and LND has not been reported to be applied to brain tumors, which are much more complex than the peripheral ones.…”

Section: Introductionmentioning

confidence: 99%

Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine

Yao

Lü

et al. 2021

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Glioma is one of the most lethal and complex tumors, and thus, an effective drug delivery system must selectively target the tumor sites and release its cargos in a controlled manner. For the first time, we combined chemotherapeutic agent doxorubicin (DOX) and chemosensitizer lonidamine (LND) to synergistically treat glioma. We also designed and prepared multitargeted redox-sensitive liposomes (Lip-SPG) co-modified with glucose and triphenylphosphonium (TPP) to effectively deliver DOX and LND for anti-glioma therapy. The anti-glioma evaluation shows that DOX and LND have a synergistic effect and Lip-SPG could further enhance their cooperation. In vitro, Lip-SPG could increase the cellular uptake and mitochondrial uptake on bEnd.3 cells and C6 cells with multitargeting ability on the brain, tumor, and mitochondria mediated by glucose and TPP. Lip-SPG can also escape from lysosomes before entering the mitochondria. The anti-glioma efficacy in vitro shows that Lip-SPG can inhibit tumor cell proliferation and induce apoptosis. In addition, Lip-SPG have a remarkable interference to mitochondria, such as reducing intracellular ATP production, inducing ROS generation, and promoting mitochondrial membrane potential depolarization. Furthermore, in vivo, the introduction of PEGylation via glutathionesensitive disulfide bonds endows Lip-SPG with favorable pharmacokinetic properties, brain targeting ability, low toxicity to normal tissues, and great anti-glioma efficacy with the survival time extended from 19 to 39 days. In conclusion, Lip-SPG are an effective delivery system for synergistically treating glioma with DOX and LND.

show abstract

Doxorubicin combined with betulinic acid or lonidamine in RGD ligand-targeted pH-sensitive micellar system for ovarian cancer treatment

Cited by 27 publications

References 39 publications

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

Application of Carbon Ion and Its Sensitizing Agent in Cancer Therapy: A Systematic Review

The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment

Glucose and Triphenylphosphonium Co-Modified Redox-Sensitive Liposomes to Synergistically Treat Glioma with Doxorubicin and Lonidamine

Contact Info

Product

Resources

About